US Patent

US10786511 — Method for treating cancer

Formulation · Assigned to Eisai R&D Management Co Ltd · Expires 2035-12-19 · 10y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions containing EZH2 inhibitors for use in cancer therapy.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: US10786511
Jurisdiction: US
Classification: Formulation
Expires: 2035-12-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.